Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma

NCT06805305 is registered in ClinicalTrials.gov with Diakonos Oncology Corporation as lead sponsor.

NCT NCT06805305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06805305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma
Lead sponsor
Diakonos Oncology Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
March 17, 2025
Completion date
March 31, 2032
Enrollment
180 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm)